Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares [Yahoo! Finance]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Yahoo! Finance
Exited 126,000 shares in TG Therapeutics. The stake previously represented 1.0% of fund AUM as of the prior quarter Top holdings after the filing: NASDAQ: QCOM: $4.7 million (1.1% of AUM) NYSE: ETSY: $4.7 million (1.1% of AUM) NYSE: UI: $4.6 million (1.1% of AUM) NYSE: UNFI: $4.2 million (1.0% of AUM) NASDAQ: CHTR: $3.9 million (1.0% of AUM) Metric Value Revenue (TTM) $531.9 million Net income (TTM) $447.5 million Price (as of market close Jan. 30) One-year price change TG Therapeutics is a commercial-stage biotechnology company specializing in innovative therapies for B-cell malignancies and autoimmune diseases. It leverages a diversified pipeline of monoclonal antibodies and small-molecule inhibitors, positioning itself to address unmet needs in hematologic oncology and immunology. With a focus on both development and commercialization, TG Therapeutics aims to expand its market presence through strategic partnerships and a robust clinical program.
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics (NASDAQ:TGTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $49.00 to $46.00. They now have an "overweight" rating on the stock.MarketBeat
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumGlobeNewswire
- TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- TG Therapeutics (NASDAQ:TGTX) was given a new $39.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a "neutral" rating on the stock.MarketBeat
- TG Therapeutics (NASDAQ:TGTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
TGTX
Earnings
- 11/3/25 - Beat
TGTX
Sec Filings
- 1/29/26 - Form 4
- 1/13/26 - Form 8-K
- 1/9/26 - Form 4
- TGTX's page on the SEC website